Literature DB >> 23148618

Targeting neddylation in cancer therapy.

Kristal Duncan1, Georgia Schäfer, Akhona Vava, M Iqbal Parker, Luiz F Zerbini.   

Abstract

The neddylation conjugation pathway has a pivotal role in mediating ubiquitination of proteins and regulation of numerous biological processes. Dysregulation in the ubiquitination and neddylation pathways is associated with many cancers. Ubiquitination involves covalent attachment of ubiquitin to target proteins, leading to protein degradation by the proteasome system. The activity of the E3-ubiquitin ligase family, cullin-RING ligases, is essential for promoting ubiquitin transfer to the appropriate substrates. Neddylation, a process mediated by the protein NEDD8, is required for conformational changes of cullins, a scaffolding protein situated in the core of cullin-RING ligases, and regulation of E3 ligase activity. In this review, we present a comprehensive discussion of the recent findings on the neddylation pathway and its importance during tumorigenesis. The ramifications regarding the potential therapeutic use of ubiquination and neddylation inhibition are also discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23148618     DOI: 10.2217/fon.12.131

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  16 in total

1.  MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors.

Authors:  K L B Knorr; P A Schneider; X W Meng; H Dai; B D Smith; A D Hess; J E Karp; S H Kaufmann
Journal:  Cell Death Differ       Date:  2015-06-05       Impact factor: 15.828

2.  The NEDD8 inhibitor MLN4924 increases the size of the nucleolus and activates p53 through the ribosomal-Mdm2 pathway.

Authors:  A Bailly; A Perrin; L J Bou Malhab; E Pion; M Larance; M Nagala; P Smith; M-F O'Donohue; P-E Gleizes; J Zomerdijk; A I Lamond; D P Xirodimas
Journal:  Oncogene       Date:  2015-04-13       Impact factor: 9.867

3.  Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells.

Authors:  Yanchun Wang; Zhongguang Luo; Yongfu Pan; Weige Wang; Xiaoyan Zhou; Lak Shin Jeong; Yiwei Chu; Jie Liu; Lijun Jia
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 4.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29

Review 5.  Neddylation and deneddylation in cardiac biology.

Authors:  Sridhar Kandala; Il-Man Kim; Huabo Su
Journal:  Am J Cardiovasc Dis       Date:  2014-12-29

6.  Tumor-associated antigen Prame targets tumor suppressor p14/ARF for degradation as the  receptor protein of CRL2Prame complex.

Authors:  Wenjuan Zhang; Lihui Li; Lili Cai; Yupei Liang; Junfeng Xu; Yue Liu; Lisha Zhou; Chen Ding; Yanmei Zhang; Hu Zhao; Jun Qin; Zhimin Shao; Wenyi Wei; Lijun Jia
Journal:  Cell Death Differ       Date:  2021-01-27       Impact factor: 15.828

7.  Expression of neddylation-related proteins in melanoma cell lines and the effect of neddylation on melanoma proliferation.

Authors:  Fang Cheng; Runzhi He; Lei Zhang; Hui Li; Wei Zhang; Xiaolin Ji; Fanting Kong; Jianfang Sun; Shubo Chen
Journal:  Oncol Lett       Date:  2014-03-07       Impact factor: 2.967

Review 8.  Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway.

Authors:  Ian Collins; Hannah Wang; John J Caldwell; Raj Chopra
Journal:  Biochem J       Date:  2017-03-15       Impact factor: 3.857

Review 9.  Impact of posttranslational modifications in pancreatic carcinogenesis and treatments.

Authors:  Nianhong Chen; Qiaoqiao Zheng; Guoqing Wan; Feng Guo; Xiaobin Zeng; Ping Shi
Journal:  Cancer Metastasis Rev       Date:  2021-08-03       Impact factor: 9.264

Review 10.  Role of novel histone modifications in cancer.

Authors:  Muthu K Shanmugam; Frank Arfuso; Surendar Arumugam; Arunachalam Chinnathambi; Bian Jinsong; Sudha Warrier; Ling Zhi Wang; Alan Prem Kumar; Kwang Seok Ahn; Gautam Sethi; Manikandan Lakshmanan
Journal:  Oncotarget       Date:  2017-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.